Dr. Apolo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10 Center Dr Rm 12n226
Bethesda, MD 20892Phone+1 301-480-0536- Is this information wrong?
Summary
- Dr. Apolo is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Albert Einstein College of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2006 - 2025
Clinical Trials
- TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Start of enrollment: 2011 Mar 01
- Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Start of enrollment: 2011 Sep 26
- Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Start of enrollment: 2012 Feb 16
- Join now to see all
Publications & Presentations
PubMed
- Organ preservation in muscle-invasive urothelial bladder cancer.Peter B Schiff, William C Huang, Scot A Niglio, Juhi M Purswani, Jonathan W Lischalk, Andrea B Apolo, Katie S Murray> ;Current Opinion in Oncology. 2024 May 1
- The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.Chandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, Yuen San Chan, Danthasinghe Waduge Badrajee Piyarathna, Lacey Elizabeth Dobrolecki, David J H Shih, Zhongc...> ;Nature Communications. 2024 Feb 14
- 2 citationsDefinitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Canc...Ashish M Kamat, Andrea B Apolo, Marek Babjuk, Trinity J Bivalacqua, Peter C Black, Roger Buckley, Matthew T Campbell, Eva Compérat, Jason A Efstathiou, Petros Grivas, ...> ;Journal of Clinical Oncology. 2023 Dec 10
- Join now to see all
Press Mentions
Atezolizumab Does Not Demonstrate Significant OS Benefit Compared with Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 26th, 2023- Exploratory Data for Treatments in Advanced Bladder Cancer - Joaquim BellmuntJanuary 31st, 2023
- Sex After Bladder CancerMay 4th, 2022
- Join now to see all
Hospital Affiliations
NIH Clinical CenterBethesda, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
